OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Total Non-current Liabilities
All obligations due after more than one year.
OptimizeRx CorporationNASDAQ: OPRX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 18.0% from a year ago
Total non-current liabilities stood at $27.19M at the end of Q1 FY2026, down 18.0% from a year earlier and down 0.6% from the prior quarter. Over 3 fiscal years it compounded at +474.2% a year.
Context
- Total non-current liabilities amounted to 16.3% of total assets at the end of Q1 FY2026, down 3.5 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -18.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.36M USD
- Year-over-year change
- -23.0%
- 4-year CAGR
- +227.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.36M | -23.0% |
| FY2024 | 2024-12-31 | 35.52M | -8.8% |
| FY2023 | 2023-12-31 | 38.94M | +26841.9% |
| FY2022 | 2022-12-31 | 144.53K | -38.9% |
| FY2021 | 2021-12-31 | 236.73K | — |
Total Non-current Liabilities vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -18.0% is the 7th highest of 10, against a peer median of -15.2%.
- Total non-current liabilities amounts to 16.3% of total assets for OPRX, versus a peer median of 4.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $183.64M USD | -15.2% | -26.4% | 35.7% | |
| Mar 2026 | $167.35M USD | -0.8% | +2.5% | 41.1% | |
| Mar 2026 | $82.59M USD | +21.9% | +49.9% | 61.4% | |
| Mar 2026 | $64.71M USD | +101.2% | +57.3% | 41.2% | |
| Mar 2026 | $27.19M USD | -18.0% | +474.2% | 16.3% | |
| Mar 2026 | $9.48M USD | -20.8% | -17.5% | 4.9% | |
| Mar 2026 | $9.32M USD | -15.2% | -38.8% | 3.1% | |
| Mar 2026 | $1.99M USD | +321.1% | +15.4% | 0.3% | |
| Feb 2026 | $370K USD | -68.7% | -55.1% | 0.3% | |
| Mar 2026 | CA$0 CAD | -100.0% | -16.9% | 0.0% | |
| Peer median (excluding OPRX) | — | -15.2% | -16.9% | 4.9% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84.68M | 18.21M | 13.85M | 13.38M | 23.37M |
| Short-term Investments | 0 | 55.93M | 0 | 0 | 0 |
| Net Receivables | 24.8M | 22.16M | 37.29M | 38.21M | 37.75M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 608.15K | 473.65K | 404.47K | 387K | 752K |
| Total Current Assets | 115.11M | 98.58M | 54.33M | 53.97M | 64.72M |
| Property, Plant & Equipment (Net) | 472.64K | 372.77K | 722.3K | 516K | 510K |
| Goodwill | 14.74M | 22.67M | 78.36M | 70.87M | 70.87M |
| Intangible Assets | 10.65M | 13.02M | 49.4M | 45.52M | 40.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.86K | 5.05K | 568.05K | 296K | 28K |
| Total Non-current Assets | 25.87M | 36.07M | 129.04M | 117.2M | 112.2M |
| Total Assets | 140.99M | 134.65M | 183.37M | 171.17M | 176.92M |
| Account Payables | 606.81K | 1.55M | 2.23M | 2.16M | 1.64M |
| Short-term Debt | 0 | 0 | 2M | 2M | 4.26M |
| Tax Payables | 0 | 0 | 49K | 318K | 0 |
| Deferred Revenue | 1.39M | 164.31K | 171.84K | 473K | 503K |
| Other Current Liabilities | 0 | 0 | 5.55M | 0 | 3.09M |
| Total Current Liabilities | 9.37M | 8.4M | 17.88M | 18.65M | 21.26M |
| Long-term Debt | 0 | 0 | 34.23M | 30.82M | 21.42M |
| Deferred Tax Liabilities | 0 | 0 | 4.34M | 4.49M | 5.71M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 236.73K | 144.53K | 38.94M | 35.52M | 27.36M |
| Total Liabilities | 9.61M | 8.54M | 56.82M | 54.17M | 48.62M |
| Common Stock | 17.86K | 18.29K | 19.9K | 20K | 20K |
| Retained Earnings | (35.25M) | (46.69M) | (64.26M) | (84.37M) | (79.24M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 131.38M | 126.11M | 126.55M | 117M | 128.29M |
| Total Debt | 327.71K | 234.43K | 36.82M | 33.19M | 26.1M |
| Net Debt | (84.35M) | (17.97M) | 22.97M | 19.81M | 2.74M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.